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Abstract
Previously, we demonstrated that allopregnanolone (APa) promoted proliferation of rodent and human neural progenitor
cells in vitro. Further, we demonstrated that APa promoted neurogenesis in the hippocampal subgranular zone (SGZ) and
reversed learning and memory deficits in the male triple transgenic mouse model of Alzheimer’s (3xTgAD). In the current
study, we determined the efficacy of APa to promote the survival of newly generated neural cells while simultaneously
reducing Alzheimer’s disease (AD) pathology in the 3xTgAD male mouse model. Comparative analyses between three
different APa treatment regimens indicated that APa administered 1/week for 6 months was maximally efficacious for
simultaneous promotion of neurogenesis and survival of newly generated cells and reduction of AD pathology. We further
investigated the efficacy of APa to impact Ab burden. Treatment was initiated either prior to or post intraneuronal Ab
accumulation. Results indicated that APa administered 1/week for 6 months significantly increased survival of newly
generated neurons and simultaneously reduced Ab pathology with greatest efficacy in the pre-pathology treatment group.
APa significantly reduced Ab generation in hippocampus, cortex, and amygdala, which was paralleled by decreased
expression of Ab-binding-alcohol-dehydrogenase. In addition, APa significantly reduced microglia activation as indicated by
reduced expression of OX42 while increasing CNPase, an oligodendrocyte myelin marker. Mechanistic analyses indicated
that pre-pathology treatment with APa increased expression of liver-X-receptor, pregnane-X-receptor, and 3-hydroxy-3-
methyl-glutaryl-CoA-reductase (HMG-CoA-R), three proteins that regulate cholesterol homeostasis and clearance from brain.
Together these findings provide preclinical evidence for the optimal treatment regimen of APa to achieve efficacy as a
disease modifying therapeutic to promote regeneration while simultaneously decreasing the pathology associated with
Alzheimer’s disease.
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Introduction
Alzheimer’s disease is the result of a multifactorial disease
process that ultimately leads to a decline in neural plasticity,
neuroregenerative capacity, and development of amyloid-beta
(Ab) plaques and neurofibrillary tangles [1]. In addition,
Alzheimer’s disease is also associated with myelination abnormal-
ities in specific brain regions that are most vulnerable to AD
pathology, including the hippocampus and entorhinal cortex [2].
Studies of quantitative volumetric magnetic resonance imaging
assessments have revealed white matter atrophy within these
regions in brains of incipient stage AD patients [3–4].
The triple transgenic mouse model of Alzheimer’s disease
(3xTgAD) mouse developed by Oddo, LaFerla and colleagues
bears mutations in three genes (human APPSWE, TauP301L, and
PS1M146V genes) linked to AD and fronto-temporal dementia and
exhibits an age-related neuropathological phenotype including
both Ab deposition and tau hyperphosphorylation [5]. Further,
similar to human AD progression, 3xTgAD mice exhibit
significant region-specific alterations in myelination and oligoden-
drocyte profile prior to the development of Ab and tau pathology
[6].
Previously, we demonstrated that allopregnanolone (APa,3 a-
hydroxy-5a-pregnan-20-one) increased proliferation of neural
progenitor cells in vitro [7]. Further, acute single administration
of APa reversed both neurogenic and cognitive deficits in vivo in
male 3xTgAD mice prior to the appearance of AD pathology [8].
We further demonstrated that APa successfully promoted
neurogenesis and reversed cognitive deficits in male 3xTgAD
mice following the onset of AD pathology. Humans with AD
display reduced levels of cortical APa, which were inversely
correlated with Braak and Braak neuropathological disease stage
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e24293[9,10]. The APOE4 allele is also associated with reduced APa
levels [10]. Aside from Alzheimer’s, APa has also been shown to
increase myelin basic protein in organotypic slice cultures of rat
cerebellum [11] and delay demyelination in Niemann-Pick C mice
[12]. The mechanism of APa induced protection of myelin
integrity is suggested to involve liver X receptor (LXR) and
pregnane X receptor (PXR) systems, important regulators of
cholesterol, fatty acid, and glucose homeostasis [13,14]. Interest-
ingly, the LXR and PXR synthetic ligand, T0901317 significantly
decreased Ab secretion and increased the expression of ABCA1,
an enzyme involved in Ab clearance, in 11-week-old APP23 mice
[15].
In this study, we first determined the optimal APa treatment
regimen to achieve regenerative benefits and reduction of AD
pathology in the male 3xTgAD mouse model. Comparative
analyses between three different APa treatment regimens
indicated that APa administered 1/week for 6 months was
maximally efficacious for simultaneous promotion of neurogenesis
and survival of newly generated cells and reduction of AD
pathology. We further investigated the impact of different
therapeutic intervention stages (pre- and post- Ab pathology) of
the 1/week/6 months APa treatment to reduce AD pathology and
preserve myelination.
Results
Determination of the Optimal APa Treatment Regimen
to Promote Regenerative Capacity and Reduce b-
Amyloid
Our previous studies indicated dose-dependent efficacy of APa
on neurogenesis [7,8]. To determine the optimal regimen for
therapeutic efficacy of APa treatment, we investigated the efficacy
of three APa treatment paradigms depicted in Figure 1A, which
were designed to determine the optimal APa treatment regimen to
both promote the regenerative capacity of the brain and to reduce
Ab pathology. Three different APa treatment regimens were
compared. The 1/month single injection of APa treatment
regimen replicated our previous approach [8] whereas the chronic
treatment 3/week/3 months and 1/week/6 months paradigms
were developed to simulate potential clinical treatment regimens.
The optimal dose of 10 mg/kg APa was based on previous
analyses [8] and was continued in this study for all three treatment
regimens. Both APa treatment regimens of a single exposure of 1/
month and 1/week/6 months APa treatment significantly
increased the survival of cells that were generated at the first
exposure to APa. The 1/week/6 months APa treatment regimen
had greater regenerative efficacy (Fig. 1B, P,0.01). However, the
3/week/3 months regimen significantly reduced regenerative
efficacy (Fig. 1B). In addition, we conducted pilot immunofluo-
rescent labeling assays to assess the efficacy of different APa
treatment regimens to reduce amyloid beta (Ab) accumulation.
Results indicated that both the 1/week/6 months regimen and the
3/week/3 months regimens significantly reduced Ab accumula-
tion in hippocampal CA1 pyramidal neurons, whereas the 1/
month single dose of 10 mg/kg APa failed to reduce Ab
accumulation (Fig. 1C). Together these data suggest that the 1/
week/6 months APa treatment regimen is optimal for APa to both
achieve regenerative efficacy and reduce Ab pathology.
Window of Therapeutic Efficacy
Upon determination that the 1/week/6 months regimen was
the optimal treatment paradigm as it induced the greatest efficacy
for promoting regenerative capacity and reducing Ab pathology,
we expanded our investigation to explore the impact of initiating
APa treatment at pre- versus post- Ab pathology. Specifically, we
initiated the 1/week/6 months APa treatment when mice were 3
months of age with no observable amyloid pathology or when
mice were 6 months of age with overt intraneuronal accumulation
of Ab [5,8]. Both treatment paradigms were for six months. Mice
treated at 3 months of age were 9 months of age at the end of
treatment when intraneuronal Ab is apparent. Mice that began
treatment at 6 months of age had intraneuronal Ab and by 12
months of age at sacrifice would have developed Ab plaques.
Allopregnanolone Promoted Survival of Newly
Generated Neural Cells
To further evaluate the short term, mid term, and long term
survival of newly generated cells in the 1/week/6 months APa
treatment paradigm, three thymidine analogs, (BrdU, IdU and
CldU) were injected at the beginning (BrdU), middle (IdU) and
end (CldU) of the experiment following injections of APa to
distinguish the survival of newly generated cells for the duration of
6 months (BrdU+), 3 months (IdU+) and one week (CldU+)
(Fig. 2A). Results from flow cytometry analysis indicated that APa
treatment of 1/week/6 months initiated at 3 months of age
significantly increased the long term (6 months; BrdU+, 98.45%
622.92) and mid term (3 months; IdU+, 68.77%618.68) survival
of newly generated cells and moderately increased the short term
(1 week; CldU+, 48.36%615.42) survival of newly generated cells
(Fig. 2B upper panel). The population of IdU positive cells was also
increased by APa treatment initiated at 6 months of age.
Allopregnanolone Reduced Ab Oligomer Accumulation
The 3xTgAD mouse model used in the current study exhibits
an age-related neuropathological progression pattern [5]. Analyses
of pathological AD phenotype confirmed that mice derived from
our colony expressed age-dependent and region specific Ab and
tau pathology (data not shown). We first characterized the
expression of different forms of Ab in 3xTgAD mice. Western
blot analyses of cortex from 3xTgAD mice revealed three major
Ab-related bands: full-length APP band at ,100 kD; oligomeric
Ab bands at ,27 kD and ,56 kD representing hexamers (6-mer)
and dodecamers (12-mer) respectively (Fig. 3A). No immunoreac-
tive bands were detected in samples derived from non-transgenic
(nonTg) mice (Fig. 3A). One 27-month 3xTgAD brain sample was
included as a positive control and confirmed an age-dependent
increase in band intensity (Fig. 3A). Because Ab 56 kD oligomer
has been proposed to be responsible for cognitive and memory
deficits in AD, our analyses focused on this oligomer and its
precursor Ab 27 kD. The 56 kD Ab oligomer is likely derived
from dimerization of the 27 kD Ab oligomers, which requires both
the availability of the 27 kD Ab oligomer and the catalytic process
of dimerization. Compared to vehicle treatment, APa treatment
partially reduced Ab*56 in both age groups, with a 2564%
reduction in the pre-pathology treatment group (n=5, P,0.01)
and 1564% reduction in the post-pathology treatment group
(n=3–4, P=0.05). APa treatment also reduced the level of Ab 6-
mer as indicated by a significant reduction in 27 kD band
(35610%, n=5,P,0.05) intensity in the pre-pathology treatment
group. In contrast, in the post-pathology treatment group, no
significant reduction of Ab 6-mer occurred (Fig. 3B). These data
indicate that pre-pathology APa treatment is reducing the
generation of the early oligomer (27 kD) and the late oligomer
(56 kD) whereas the post-pathology APa treatment appears to
selectively delay the formation of the 56 kD oligomer. In addition,
APa had no effect on APP protein expression, suggesting that APa
did not directly affect APP generation. Together these data suggest
that APa reduced the oligomerization of Ab. Additional
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blot that APa treatment induced an apparent reduction of Ab
immunoreactivity in specific brain regions including hippocampus,
cortex, and amygdala (Figure 3C).
Allopregnanolone Reduced ABAD Expression in 3xTgAD
Mice
The mitochondrial protein ABAD (amyloid-binding alcohol
dehydrogenase) is over-expressed in human AD brains [16,17,18]
and 3xTgAD mice [19]. Ab binds to ABAD and disrupts
mitochondrial function, leading to the generation of reactive
oxygen species and cellular oxidative damage [18]. In parallel to
APa-induced reduction of Ab generation, APa-treatment signif-
icantly decreased cortical expression of ABAD in the pre-
pathology group (3064%, n=3, P,0.05) and induced a trend
of reduction in the post-pathology treatment group (2067%,
n=3-4, P=0.07) (Figure 4A). Similarly, additional immunofluo-
rescent analyses revealed a qualitative reduction in ABAD
immunofluorescent intensity in APa-treated 3xTgAD mouse brain
sections relative to vehicle-treated brains (Fig. 4B). Together, APa
treatment induced a parallel reduction of Ab and ABAD
expression indicating a potential protective mechanism whereby
APa prevents Ab induced mitochondrial dysfunction [18].
Allopregnanolone Modulated Phosphorylated-tau
Expression in 3xTgAD mice
In the 3xTgAD mouse model, tau pathology has been
demonstrated to follow Ab accumulation [20]. To determine
whether the APa-induced reduction of Ab levels would lead to
reduction in tau pathology, we investigated the impact of APa on
tau phosphorylation by Western blot analysis and immunofluo-
rescent labeling with monoclonal phosphorylated-tau antibody
Figure 1. Determination of optimal allopregnanolone treatment regimen. (A). Schematic overview of three APa treatment designs and their
outcomes. (B) Impact of APa on neurogenesis in 3xTgAD mouse model. All three APa treatments were initiated when mice were 3 months old. Upon
completion of each treatment paradigm, BrdU stereology (for 3/week/3 months treatment paradigm, n=7–8/group) or flow cytometry assay (for 1/
week/6 months treatment paradigm, n=2–5/group and 1/month treatment paradigm, n=10–12/group) was used to assess neurogenesis. Both the
1/month APa treatment and the 1/week/6 months APa treatment induced a significant increase in neurogenesis, with the latter regimen yielding the
greater increase in neurogenesis. However, the 3/week/6 months treatment induced a significant decrease in neurogenesis. The percentage of
increase is presented as mean 6 SEM * P,0.01. (C) Impact of APa on Ab accumulation in 3xTgAD mouse model. Brain sections from 3xTgAD mice
treated with APa (10 mg/kg) or vehicle were stained. Ab immunoreactivity was detected with 6E10 antibody (green) and nuclei counter-stained with
DAPI (blue). Representative images indicated that the 1/week/6 months APa treatment significantly decreased 6E10 immunoreactivity and showed
the highest efficacy of Ab reduction; whereas the 3/week/3 months APa treatment had a comparable efficacy of Ab reduction and the 1/month APa
treatment showed minimal effect of reducing Ab immunoreactivity.
doi:10.1371/journal.pone.0024293.g001
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a trend towards reduction in phospho-tau band intensity in both
pre-pathology treatment and post-pathology treatment groups,
which did not reach statistical difference between APa- and
vehicle-treated samples (Fig. 5A). However, immunofluorescent
analyses indicated that APa induced a reduction in phospho-tau
immunoreactivity at 12 months in the hippocampal CA1, frontal
cortex and amygdalar regions (Figure 5B). In the pre-pathology
treatment group when mice were at 9 months of age, phospho-tau
was barely detectable.
Allopregnanolone Regulated LXR, PXR and HMG-CoA-R
Expression in 3xTgAD Mice
APa has been proposed to regulate cholesterol homeostasis via
the LXR and PXR system [21,22] and dysregulation of cholesterol
homeostasis is associated with the generation of Ab [15]. In the
current study, we investigated APa regulation of inducible liver X
receptor (LXR), pregnane X receptor (PXR) and 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMG-CoA-R) expression.
APa induced a significant increase in LXR, PXR and HMG-CoA-
R expression in the pre-pathology treatment group. In contrast, in
the post-pathology treatment group, APa treatment resulted in a
reversal of cholesterol homeostatic responses, which was particu-
larly evident in the significant reduction of PXR expression (Fig. 6).
This suggests that the effect of APa is specific to the synthesis and
clearance of cholesterol rather than the proteins involved in
cholesterol trafficking.
Allopregnanolone Treatment Inhibited Microglial
Activation
Microglial activation is well-documented in the pathogenesis of
AD and is potentially related to presence of oligomerized Ab.
Further, in a model of cholesterol dysregulation, APa inhibited
microglial activation in Niemann-Pick C mice [23]. The reduction
in the 56 kD Ab oligomer and ABAD in the post-pathology APa
treatment group would be expected to result in a reduction of
neuroinflammatory responses but to a lesser extent than the pre-
pathology group. Consistent with these results, we observed a
significant age-dependent increase in microglial activation in
3xTgAD mice as indicated by the significant increase activated
microglia expression through immunoblotting with anti-CD11b/c
(OX42) antibody, from 9 months to 12 months in the vehicle
Figure 2. Impact of optimal 1/week/6 m allopregnanolone treatment regimen on neurogenesis and survival in 3xTgAD male
mouse. (A) The paradigm of once per week for 6 months of treatment. Three-month-old (pre-detectable pathology) and six-month-old (readily
detectable pathology) male 3xTgAD mice were randomized into vehicle or APa treatment groups. APa or vehicle was subcutaneously administered
at 10 mg/kg once per week for 6 months (1/week/6 month). To assess the survival capability of newly generated cells, mice were treated with
sequential injections of BrdU for the first 5 days of the study (indicating a 6 month survival period), IdU for 5 days at the midpoint (indicating a 3
month survival period), and CldU 5 days before completion of the study (indicating a short term survival period). After 6 months of APa treatment,
mice at 9- and 12-months-old were sacrificed. (B) Impact of survival of newly generated cells in hippocampus subgranular zone (SGZ). Flow cytometry
analysis showed APa treatment (1/week/6 months) significantly increased IdU positive cells in 9-month-old (upper panel) and 12-month-old mice
(lower panel); BrdU positive cells were increased in 9-month-old mice (upper panel). CldU positive cells were not significantly increased in both ages
suggesting that this APa treatment regimen sustained survival of newly generated cells, and that neurogenic capacity of APa decreased with age.
The percentage increase was presented as mean 6 SEM; * P,0.01; n=2–5/group.
doi:10.1371/journal.pone.0024293.g002
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vehicle control, APa treatment in 3xTgAD mice significantly
decreased OX42 expression level in both the pre-pathology
treatment (26.264.6%, P,0.05) and the post-pathology treatment
group (18.067.4%, P=0.05) (Fig.7A). Further immunofluorescent
labeling with rabbit polyclonal anti-Iba1, another activated
microglia marker, revealed APa treatment induced reduction of
microglia immunoreactivity in hippocampal CA1 region (Fig. 7B).
Allopregnanolone Increased a Marker of Myelination in
Brains of 3xTgAD Mice
Decline in myelination is a neuropathological consequence in
the 3xTgAD animal model [6]. APa-enhanced myelination has
been reported in Niemann-Pick C mice [23]. To investigate the
therapeutic potential of APa to delay or reverse myelination
deficits that occur in human AD [24,25] and in 3xTgAD mice, we
investigated the impact of APa on myelin expression in 3xTgAD
mouse brain. APa induced a significant increase in the expression
of CNPase, a marker of oligodendrocytes and myelin, relative to
vehicle control by 40% in nonTg (P,0.01, n=3) and 50% in
3xTgAD (P,0.05, n=3) mice in the pre-pathology treatment
group (Fig. 8A). Similarly, in the post-pathology treatment group,
APa treatment also induced a 30% increase in CNPase levels in
3xTgAD mice (P,0.05, n=3–4) (Fig. 8A). In the nonTg group,
expression of CNPase increased in the 12-month-old vehicle group
compared to 9-month-old vehicle, in which CNPase expression
was not increased by APa (Fig. 8A). Immunofluorescent labeling
with the same antibody revealed a region-specific increase in
CNPase immunoreactivity in the hippocampal CA1 (B), entorh-
inal cortex (C) and primary somatosensory cortex (D) (Fig. 8B).
Figure 3. Allopregnanolone reduced expression of Ab oligomers in 9- and 12-month-old male 3xTgAD mice. Equal amounts of frontal-
parietal-temporal cortex samples from 3xTgAD mice treated with APa (10 mg/kg) or vehicle were loaded onto the gel. Ab expression was determined
with Ab antibody 6E10 by immunoblot analysis. (A) Three major immunoreactive bands were detected in the samples from 9 and 12 month old
3xTgAD mouse brains. Full-length APP band was detected at ,100 kD. The bands at ,27 kD and 56 kD indicated Ab hexamers (6-mer) and Ab
dodecamers (12-mer) respectively. One 27-month old 3xTgAD cortex sample was included as a positive control. (B) For better separation of the Ab 56
and 27 kD bands, a 10–20% gradient gel was used to analyze the effects of APa on Ab oligomers. APa treatment significantly reduced Ab 56 kD
oligomer in the pre-pathology treatment (2564%, n=5,P,0.01) and the post-pathology treatment (1564%, n=3–4, P=0.05) groups. Ab 6-mer at
,27 kDa was also significantly reduced by APa treatment in the pre-pathology treatment group (35610%, P,0.05). Bars represent mean relative
expression 6 SEM (* P#0.05 and ** P,0.01 compared with vehicle control group). (C) Region specific reduction in Ab IR by APa treatment in 3xTgAD
brains. Representative images of Ab immunostaining indicated a significant decrease of Ab IR in the hippocampus and amygdala in APa-treated
3xTgAD mice relative to vehicle.
doi:10.1371/journal.pone.0024293.g003
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3xTgAD mice. Equal amounts of frontal-parietal-temporal cortex
samples from 3xTgAD mice treated with APa (10 mg/kg) or vehicle
were loaded onto the gel. Ab-binding alcohol dehydrogenase (ABAD)
was probed with antibody ERAB (1:500, Abcam) by immunoblot
analysis. (A) APa-treatment significantly decreased ABAD levels in both
the pre-pathology group (3064%, n=3, P,0.05) and the post-
pathology treatment group (2067%, n=3–4, P=0.07). Bars represent
mean relative expression 6 SEM; * P,0.05 compared with vehicle
control group. (B) Confirmation of reduced ABAD expression by
immunohistochemistry. Representative image of ABAD immunostain-
ing in 3xTgAD mouse brain sections confirmed the results from
immunoblots. There were much less ABAD immunoreactive cells seen
in APa-treated brains relative to vehicle-treated brains.
doi:10.1371/journal.pone.0024293.g004
Figure 5. Allopregnanolone modulated phospho-tau expres-
sion in 3xTgAD mice. Equal amounts of frontal-parietal-temporal
cortex samples from 3xTgAD mice treated with APa (10 mg/kg) or
vehicle were loaded onto the gel. Phospho-tau expression was
determined with phospho-tau antibody AT8 by immunoblot analysis.
(A) No significant reduction of AT8 signal in APa-treated samples. Bars
represent mean relative expression 6 SEM. (B) Region-specific
reduction of AT8 immunostaining in the hippocampus, cortex and
amygdala in APa-treated mice. Representative image of AT8 immuno-
staining in 3xTgAD mouse brain sections indicated lower immunore-
activity in the hippocampus, cortex and amygdala of APa-treated mice
relative to vehicle control.
doi:10.1371/journal.pone.0024293.g005
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Regenerative therapeutics that target AD pathology and
the disease process
Previously we demonstrated that APa reversed neurogenic and
cognitive deficits in the male 3xTgAD mouse model of
Alzheimer’s [8]. APa was efficacious in the 6- and 9-month old
3xTgAD mice on both neurogenesis and associative learning and
memory and was comparable to their respective age-matched
nonTg controls which corresponded to a 100% or more increase
in response induced by APa [8,26].
In vehicle-treated mice, there was a substantial age-related
decline in neurogenesis that was exacerbated in 3xTgAD mice.
Between 3 and 6 months there was a 78% decline and between 6
and 9 months there was another 58% decline, similarly an 18%
decline was observed between 9 and 12 months [8,26]. At 12
months of age in the 3xTgAD, APa no longer increased
neurogenesis nor did it promote survival of neural progenitors.
When extraneuronal Ab plaques were present in the 12-month-old
3xTgAD mice, APa was ineffective in reversing the profound
neurogenic and cognitive deficits of these mice. This is specific to
the transgenic genotype because APa promoted neurogenesis and
neuroprogenitor survival in the 15 month nonTg mice [26].
Treatment with APa increased neural progenitor survival and
restored learning and memory to that of 12-month-old nonTg
mice [26]. By the time 3xTgAD mice reached 12 months of age
either the progenitor population was sufficiently depleted or the
mechanisms by which APa promotes neuroproliferation and/or
survival were no longer present and/or functional.
In the current study, we determined the efficacy of APa to
promote the survival of newly generated neural cells while
simultaneously reducing Alzheimer’s disease (AD) pathology in
the same mouse model with different APa treatment regimens.
APa treatment paradigms included 1/month, 3/week/3 months,
or 1/week/6 months, and were developed to simulate potential
clinical regimens. The 1/month APa treatment regimen was
efficacious in promoting neurogenesis and reversing cognitive
deficits whereas it had no effect on AD pathology. In contrast, the
most frequent treatment paradigm, 3/week/3 months APa was
most efficacious for reducing AD pathology whereas it was least
effective at promoting neurogenesis. Subsequent analyses indicat-
ed that APa (10 mg/kg) administered 1/week/6 months achieved
an optimal balance between promoting neurogenesis and reducing
intracellular b-amyloid accumulation.
Oligomeric Ab species in the brain are considered the major
toxic form of Ab, and activate a detrimental cascade that leads to
neuronal loss, cognitive decline, and eventually AD diagnosis
[1,27,28,29,30,31,32]. Increasing evidence indicates that treat-
ments initiated late in the disease process, i.e. dense and wide
distribution of Ab plaques, have a low probability of clinical
success [33] suggesting that targeting the early phase of oligomeric
Ab generation may have greater clinical efficacy. Results
demonstrated that APa administered 1/week/6 months signifi-
cantly increased survival of newly-generated neurons and
simultaneously reduced Ab pathology in both age groups. While
AP significantly reduced the 56 kD Ab oligomer in both the pre-
pathology and post-pathology groups, greatest efficacy was
observed when APa was administered in the pre-pathology phase
Figure 6. Allopregnanolone increased HMG-CoA-R, LXR and PXR expression in 9-month-old male 3xTgAD mice. Equal amounts of
frontal-parietal-temporal cortex samples from 3xTgAD mice treated with APa (10 mg/kg) or vehicle were loaded onto the gel. Liver X Receptor (LXR),
Pregnane X Receptor (PXR) or 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase (HMG-CoA-R), were determined with LXR, PXR, or HMG-CoA-R
antibodies by immunoblot analysis. APa treatment increased the level of HMG-CoA-R (84%, P=0.05), LXR (91%, P,0.05), and PXR (56%, P,0.05) in
the pre-pathology treatment group. Bars represent mean relative expression 6 SEM; * P#0.05 compared with vehicle control group.
doi:10.1371/journal.pone.0024293.g006
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Consistent with the biochemical results, Ab immunoreactivity was
reduced in hippocampal CA1 and moderately reduced in frontal
cortex, amygdala and subiculum. Ab binding alcohol dehydroge-
nase, a mitochondrial Ab binding enzyme, was reduced in parallel
with Ab by APa treatment. ABAD has been well-demonstrated to
interact with Ab within mitochondria and cause mitochondrial
dysfunction [16]. In AD patients and the 3xTgAD mice, ABAD
expression parallels severity of Ab load [19]. Based on these
findings, reduction of both Ab and ABAD load with APa
treatment would be predicted to prevent the exacerbation of
mitochondrial deficits associated with AD and therefore delay or
prevent disease progression.
In this mouse model, phosphorylated-tau follows severity of Ab
accumulation [34]. The APa-induced reduction in intraneuronal
b-amyloid was accompanied by a moderate, although not
statistically significant, brain-wide reduction in phosphorylated-
tau with the greatest reduction of phosphorylated-tau in AD-
vulnerable brain regions. The reduction of tau pathology by APa
can likely be attributed to the reduction in Ab load. Microglial
activation is a well-documented response to AD pathology
[35,36,37]. In parallel to the reduction of Ab and phospho-tau,
APa treatment significantly reduced microglial activation as
indicated by reduced expression of OX42. While the reduction
in microglia activation by APa is likely a consequence of APa-
induced reduction of AD pathology, suppression of microglial
activation would relieve the inflammatory burden associated with
AD pathology.
White matter abnormalities have been widely reported in AD
[2,3,4,38] and observed in the 3xTgAD mouse brain as well [6]. In
the 3xTgAD mouse brain, abnormal myelination and loss of
axonal integrity occur in the same brain regions vulnerable to AD
pathology in humans [6]. In the present study, we found that in
parallel to reduction of AD pathology, APa treatment also
increased a marker of myelination in these same brain regions.
Collectively, results of these analyses demonstrate the concomitant
reduction by APa of four major pathological markers of AD, Ab,
phospho-tau, microglial activation and white matter loss, and
provide pre-clinical evidence in support of the efficacy of APa to
decrease and delay development of AD pathology.
Increasing evidence indicates that altered cholesterol metabo-
lism is linked to AD pathology [39,40]. Mechanistic analyses
indicated that 1/week APa begun at 3 months and continued for 6
months increased expression of LXR, PXR, and HMG-CoA
reductase, three proteins that regulate cholesterol homeostasis.
LXR, a nuclear hormone receptor abundant in the brain [41], acts
as a molecular sensor of cholesterol levels and initiates cholesterol
clearance [15]. LXR activation increases cholesterol efflux
through up-regulating ABCA1 and ApoE expression, and prevents
the hyper-activation of c-secretase and over-production of Ab
[15,42,43]. LXR activation has been demonstrated to improve
cognitive function in multiple mouse models of amyloidogenesis
[15,44,45,46,47].
LXR ligands frequently activate PXR [48]. Results from our
analyses indicated that in parallel with an APa-induced increase in
LXR expression in the pre-pathology condition, APa also
increased PXR expression in the pre-pathology 3xTgAD mouse
brain. PXR activation induces CYP3A enzymes including
CYP3A4 and CYP3A13 and leads to cholesterol hydroxylation
and activation of organic anion transporters for cholesterol
extrusion [49]. The APa induced increase in brain LXR and
PXR leads to increased cholesterol efflux, thereby reducing c-
secretase activation by cholesterol-laden lipid rafts. Increased
cholesterol efflux provides a plausible mechanism to explain how
Figure 7. Allopregnanolone treatment inhibited microglial
activation. Equal amounts of frontal-parietal-temporal cortex samples
from 3xTgAD mice treated with APa (10 mg/kg) or vehicle were loaded
onto the gel. Microglial activation was determined with anti-CD11b/c
(OX42) antibody by immunoblot analysis. (A) APa treatment signifi-
cantly decreased OX42 expression in both the pre-pathology treatment
group (26.264.6%, P,0.05) and the post-pathology treatment group
(18.067.4%, P=0.05). Bars represent mean relative expression 6 SEM;
* P#0.05. (B) Reduction in microglial staining by APa treatment in
hippocampal CA1 region. Representative image of immunofluorescent
staining with microglial marker anti-Iba1 in 3xTgAD brains indicated
substantial reduction of reactive microglia in the hippocampal CA1
region in APa treated 3xTgAD mice relative to vehicle (Iba1-labeled
microglia cells shown in red and DAPI-labeled nuclei shown in blue).
doi:10.1371/journal.pone.0024293.g007
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intraneuronal Ab oligomers.
To determine whether APa primarily effected cholesterol
homeostatic mechanisms primarily in brain, we investigated
LXR and PXR expression in liver. Further, these analyses would
also address whether the vehicle (2-hydroxypropyl-b-cyclodextrin),
which can reduce cholesterol in other tissues, would also affect
expression of HMG Co-A reductase, LXR and PXR in liver. To
address these issues, we conducted Western blot analysis for LXR
and PXR expression in liver. Results of these analyses indicated no
significant effect of APa on LXR or PXR expression in liver (data
not shown). These data support our findings indicating that APa is
primarily affecting cholesterol homeostasis in brain without
affecting peripheral cholesterol.
These findings in the 3xTgAD mouse brain are consistent with
APa induced activation of a PXR pathway in cholesterol
trafficking in the Niemann-Pick C Disease mouse model [22].
APa-induced reduction of AD pathology burden is also consistent
with the findings of Mellon and colleagues who reported that APa
delayed progression of Niemann-Pick C Disease in a mouse model
[23,52,53]. In young animals, either single or multiple injections of
APa protected cerebellar Purkinje cells from degeneration and
increased animal life span [52]. Less improvement was observed at
older ages of Niemann-Pick C12/2 mouse that had disrupted
neurosteroidogenesis [52]. APa induced a delay in progression of
pathology and enhanced survival of Niemann-Pick C mice
through a PXR-mediated mechanism [22].
Our study also revealed that APa induces an increase in HMG-
CoA reductase protein expression. The increase in HMG-CoA
reductase is at first paradoxical as it is the rate-limiting enzyme in
cholesterol synthesis. HMG-CoA reductase is also required for
oxysterol generation which is well documented to activate LXR
and PXR-mediated gene transcription for cholesterol and lipid
transport proteins [40]. If this hypothesis is correct, it would
predict decreased activation of c-secretase by cholesterol and lipid
laden lipid rafts.
In this study, an interesting and consistent finding was that the
pre-pathology treatment exhibited a greater magnitude of efficacy
in terms of promoting survival of neural progenitors, reducing Ab
pathology, suppressing inflammatory response, and activating
LXR/PXR pathways involved in cholesterol homeostasis and Ab
clearance. These findings indicate that early development of
pathology serves as a critical stage for APa therapeutic efficacy
that coincides with intraneuronal Ab accumulation. The appear-
ance of Ab plaques coincides with cessation of APa efficacy. One
potential reason for this cessation is that Ab has been transported
Figure 8. Allopregnanolone increased myelination in brain of 3xTgAD mice. Equal amount of frontal-parietal-temporal cortex samples from
3xTgAD mice treated with APa (10 mg/kg) or vehicle were loaded onto the gel. The expression of CNPase was measured using anti-CNPase antibody
by immunoblot analysis as an indicator of oligodendrocytes and myelination. (A) APa treatment significantly increased CNPase expression in the pre-
pathology group in both nonTg (P,0.01) and 3xTgAD mice (P,0.05). No significant change in CNPase expression was observed in the post-
pathology treatment group in nonTg mice between APa treatment and the vehicle control. However, in 3xTgAD mice, APa treatment significantly
increased CNPase expression (P,0.05). Bars represent mean relative expression values of CNPase relative to b-actin 6 SEM; * P,0.05 and ** P,0.01
compared with vehicle control group. (B–D) Region-specific enhancement of myelination was observed in APa-treated mice. Representative image of
CNPase immunostaining showed greater immunoreactivity in the hippocampal CA1 (B), entorhinal cortex (C) and primary somatosensory cortex (D)
regions of APa-treated 3xTgAD mice.
doi:10.1371/journal.pone.0024293.g008
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accumulation is a determining factor in efficacy of APa which is
paralleled by the lack of efficacy once intraneuronal Ab is
extracellularly localized. The well-established relationship between
cholesterol homeostasis and Ab generation coupled with our
findings of APa induced pathways of cholesterol homeostasis
coinciding with intracellular Ab, suggest that these two systems,
i.e. cholesterol homeostasis and intraneuronal Ab and APa
efficacy are coupled.
The deposition of Ab in the extracellular compartment
disconnects this coupled pathway, leading to a loss of efficacy of
APa. Our data indicate that the presence of intraneuronal Ab is
the key regulatory factor in determining therapeutic efficacy.
Although the molecular content of extracellular and intraneuronal
Ab may be similar, their localization is a key indicator of cellular
adaptation and therapeutic regulation.
Translational implications for the optimal therapeutic
regimen
APa induction of neurogenesis [7,8], recovery of learning and
memory function [8], and reduction of AD pathology burden
provides pre-clinical evidence for APa as a multifaceted
regenerative therapeutic. Moreover, APa induction of cell cycle
gene expression [7] and key regulators of cholesterol homeostasis
provides mechanistic plausibility for its therapeutic efficacy to
promote neurogenesis and cognitive function while reducing AD
pathology. Two factors are critical to the regimen of APa to
achieve therapeutic efficacy. The first of these factors is the
temporal regimen of administration. Our data show that
regeneration is achieved with either 1/month or 1/week regimen
of APa. Reduction of AD pathology can be achieved with 1/week
or 3/week regimen. The combination of regeneration and
reduction of pathology was only achievable with the 1/week
APa treatment regimen. The second regulating factor is the type
of pathology. Administration of APa prior to and during the early
stages of AD pathology (intraneuronal Ab) was efficacious in
reducing the burden of pathology. APa treatment initiated at the
stage of Ab plaque development was associated with reduction in
efficacy. These findings predict that APa therapeutic benefit in
humans would be most efficacious to delay progression of AD
when brains still have neurogenic and myelination capacity.
Target populations could include those with very early stage
genetically mediated familial AD and those diagnosed with mild
cognitive impairment (MCI).
Materials and Methods
Animal Treatments and Ethics
All rodent experiments were performed following National
Institutes of Health guidelines on use of laboratory animals and an
approved protocol by the University of Southern California
Institutional Animal Care and Use Committee (Protocol Number:
11156). The presented study has been approved by the University
of Southern California Institutional Animal Care and Use
Committee (Ethics Committee).
Transgenic Mice
Colonies of 3xTgAD (3xTgAD, homozygous mutant of human
APPswe and tauP301L and PS1M146V) and nonTg mouse strain
(C57BL6/129S; Gift from Dr. Frank LaFerla, University of
California, Irvine) [5] were bred and maintained at the University
of Southern California (Los Angeles, CA) following National
Institutes of Health guidelines on use of laboratory animals and an
approved protocol by the University of Southern California
Institutional Animal Care and Use Committee. In addition, the
minimal number of required animals was used for these
experiments and pain was minimized. Mice were housed on
12 h light/dark cycles and provided with ad libitum access to food
and water. The characterization of amyloid and tau pathologies,
as well as synaptic dysfunction in this line of mice has been
described previously [20,54] and confirmed in our laboratory. The
mice were genotyped regularly to confirm the purity of the colony.
To ensure the stability of AD-like phenotype in the 3xTgAD
mouse colony, we performed routine immunohistological assays
every three to four generations. Only offspring from breeders that
exhibited stable AD pathology were randomized into the study.
The number of mice per condition is indicated within the results
section. Experiments were performed using three- and six-month-
old male 3xTgAD and age-matched nonTg mice.
Drug Preparation
Allopregnanolone (APa 3a-hydroxy-5a-pregnan-20-one) (aka
AP, Allo or THP) used for this study was purchased from
Steraloids, Inc. (Newport, Rhode Island, USA). APa was dissolved
in 22.5% (W/V) (2-hydroxypropyl)-b-cyclodextrin (Sigma, St.
Louis, MO) solution at APa 2.5 mg/ml by brief sonication and
was subcutaneously injected to mice at APa 10 mg/kg body
weight. b-cyclodextrin alone was included as vehicle control.
Thymidine analogues, 5-Bromo-29-deoxyuridine (BrdU), 5-
Chloro-29-deoxyuridine (CldU) and iodo-deoxyuridine (IdU), used
in this study were purchased from Sigma. These analogues were
dissolved in PBS and intraperitoneally (i.p.) injected following or
during APa treatment at 100 mg/kg.
Treatment paradigms
Three different APa treatment paradigms were adopted to
determine the optimal APa treatment regimen to promote
regenerative capacity and simultaneous reduce AD pathology.
Details of these treatment paradigms are listed below (Figure 1A):
Paradigm 1. Three-month-old male 3xTgAD mice were
injected with either APa (10 mg/kg) or vehicle once and analyzed
1 month later (1/month). One hour after APa injection, mice were
injected with BrdU (100 mg/kg). Mice were sacrificed 27 days
after APa administration for cell survival assessment.
Paradigm 2. APa was injected to mice once a week for 6
months (1/week/6 months). In order to investigate whether APa
treatment could prevent or reverse AD-related pathologies, we
chose 3- and 6-month-old 3xTgAD and age-matched nonTg mice
for the experiments on our previous observation that detectable
intraneuronal Ab pathology starts at about 6 months of age in the
male 3xTgAD model, whereas tau pathology follows Ab pathology
development and is detectable at older age [5]. During APa
(10 mg/kg) treatment, mice were treated with sequential injections
of BrdU (100 mg/kg) at the first 5 days of the study, IdU (100 mg/
kg) for 5 days at the midpoint, and CldU (100 mg/kg) 5 days
before completion of the study. After 6 months of treatment, mice
at 9 and 12 months of age were sacrificed.
Paradigm 3. Three-month-old male 3xTgAD mice were
injected with either APa (10 mg/kg) or vehicle once every other
day for 3 months (3/week/3 months). In the first five weeks, BrdU
(100 mg/kg) was injected 1 h after each APa given. One week
before sacrifice, BrdU was injected again 1 h after APa injection.
Animal Dissection and Tissue Collection
Upon completion of the treatments, animals were sacrificed.
Prior to sacrifice, mice were anesthetized with 100 mg/kg
ketamine and 10 mg/kg xylazine and perfused with pre-chilled
PBS. Brains were immediately dissected along the sagittal line into
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then stored at 280uC for biochemical analysis, and the right
hemisphere was post-fixed in 4% paraformaldehyde for immuno-
histochemical analysis. Fixed brains were embedded into blocks
(40 brain hemispheres in the same block) for cryostat sectioning by
NeuroScience Associates (NSA, Inc., Knoxville, TN). The 40-
brain hemisphere block was serially sliced into 35 mm coronal
sections and the free-floating multibrain sections were kept in
antigen preservation solution (1% Polyvinyl pyrrolidone and 50%
Ethylene glycol in PBS) at 220uC until use.
Unbiased Stereology
Number of BrdU-labeled cells was determined in every sixth
section in a series of 40 mm coronal sections using unbiased
stereology (optical dissector). The first section of each hemisphere
was randomly started at the beginning of olfactory, and serial
sections were collected to the end of the cerebellum. Systematic
samplings of unbiased counting frames of 50 mm on a side with a
200 mm matrix spacing were produced using a semiautomatic
stereology system (Zeiss Axiovert 200 M fluorescent microscope as
part of the 3iMarianas digital microscopy and a 606 SPlan
apochromat oil objective (1.4 numerical aperture)). Positive cells
that intersected the uppermost focal (exclusion) plane and those
that intersected the exclusion boundaries of the unbiased sampling
frame were excluded from analysis. Cells that met analysis criteria
through a 20 mm axial distance were counted according to the
optical dissector principle. The granule cell layer reference volume
was determined by summing the traced SGZ, granule cell areas for
each section multiplied by the distance between sections sampled.
The mean granule cell number per dissector volume was
multiplied by the reference volume to estimate the total granule
cell number. The stereologically determined number of BrdU-
positive cells was related to the granule cell layer sectional volume
and multiplied by the reference volume to estimate the total
number of BrdU-positive cells.
Flow-cytometry Analysis of BrdU, IdU, and CldU
Incorporation
Along with the study, our group developed a flow cytometry
counting method for analysis of BrdU, IdU, and CldU
incorporation. This flow cytometry analysis method has been
previously validated by direct comparison between unbiased
stereology and flow cytometry analysis [8,55]. Briefly, hippocampi
were dissected from the fixed hemispheres using anatomical
landmarks as described [56]. Extracted hippocampi were
homogenized and nuclei sample collected into a 1.5 ml micro-
centrifuge tube, washed four times using 200 ml of PBS, and then
centrifuged for 10 min at 10,000 rpm. The pellet was then
resuspended in 600 ml of PBS plus 0.5% Triton X-100, heated for
1 h at 75 Cu for epitope retrieval, and incubated for 24 h at 4 Cu
with primary mouse monoclonal anti-BrdU antibody (1:100,
Ab12219, Abcam, Cambridge, MA) for BrdU+ cell count; anti-
CldU (1:40, ab6326, Abcam) for CldU+ cell count; anti-IdU (1:20,
BD, 340649), for IdU+ cell count. The number of nuclei was
estimated by counting the propidium iodide, and the number of
BrdU-, IdU- and CldU-labeled cells was detected using Beckman
Flow Cytometry System (FC 500) with CXP Software.
Immunoblotting
Protein was extracted from cerebral cortex using T-per (Pierce)
extraction buffer complemented with Protease and Phosphatase
Inhibitor (Sigma, St. Louis, MO), followed by high-speed
centrifugation at 100,000 x g for 1 h. The supernatant was
collected as the protein extract. Protein concentrations were
determined by DC protein assay kit (Bio-Rad, Hercules, CA).
Equal amounts of protein (40–60 mg depending on the protein of
interest) were separated by SDS-PAGE on a 12% or 10–20% Bis-
Tris gel (Bio-Rad), transferred to 0.2 mm Nitrocellulose or
0.45 mm PVDF membrane (Millipore Corp., Bedford, MA).
Nonspecific binding sites were blocked with blocking buffer (5%
nonfat milk in Tris-buffered saline, TBS, containing 0.1%
Tween-20, TBST). After blocking, primary antibodies were
incubated in blocking buffer overnight at 4uC. The following
antibodies were used in this study: b-Amyloid (Ab) monoclonal
antibody, 6E10 (1:1000, Covance/Signet, Berkeley, CA); for the
abnormally processed isoforms as well as precursor forms and
oligomers of b-amyloid [27]; mouse anti-human PHF-Tau clone
AT8 (1:500, Pierce) for phosphorylated tau protein at serine 202;
rabbit polyclonal anti-CD11b/c (OX42, 1:500, Neuromics) for
microglial cells [57]; rabbit polyclonal to ERAB (1:500 Abcam)
for Ab peptide binding protein on mitochondria, rabbit
polyclonal anti-HMG-CoA reductase (1:1000, Upstate); rabbit
polyclonal anti-LXR b (1:500, Novus) for Liver X Receptor
(LXR); rabbit polyclonal anti-PXR (1:500, Novus) for Pregnane
X Receptor (PXR); CNPase (1:1000, Chemicon) an oligoden-
drocyte marker to detect myelination [6]. The membranes were
then incubated with a horseradish peroxidase-conjugated goat
anti-mouse or anti-rabbit secondary antibody (1:5,000–10,000)
complementary to the primary antibody. Blots were developed
with Supersignal West Dura Extended Duration Substrate
(Pierce) or TMB (3, 39,5 ,5 9-Tetramethylbenzidine) Substrate
kit (Vector). Results were visualized with the Chemidoc System
(Bio-Rad). Quantitative analyses of optical band intensity were
performed by BioRad Quantity One software or Un-Scan-It.
Protein expression was normalized by loading housekeeping
protein b-actin or b-tubulin.
Immunofluorescent Labeling
Free-floating multibrain sections were rinsed extensively in PBS
containing 0.1% Triton X-100 (PBST). They were blocked in
blocking buffer (PBST with 5% normal goat serum, NGS, and
0.3% Triton X-100) for 60 min, followed by incubation with
primary antibody in blocking buffer overnight at 4uC. The
following antibodies were used: b-Amyloid (A) monoclonal
antibody, 6E10 (1:1000, Signet, Cat No. 9320), mouse anti-
human PHF-Tau MAb clone AT8 (Pierce, MN1020), rabbit
polyclonal anti-Iba1 (1:1000, Wako) for microglia cells [58], goat
polyclonal anti-ERAB (C-20, 1:250, Santa Cruz) for Ab peptide
binding protein on mitochondria, CNPase (1:300, Chemicon) an
oligodendrocyte marker for labeling myelin structure of white
matter in brain. The next day, sections were rinsed 3 times with
PBST and incubated in FITC-conjugated goat anti-mouse/rabbit
(1:500, Vector Laboratories) or Cy3-conjugated goat anti-mouse/
rabbit (1:1000, GE Healthcare) secondary antibody in PBST for
60 min at room temperature. After intense washing with PBST
the sections were mounted with DAPI-containing mounting
medium on coverslips. The immunoreactivity was observed and
images were captured with the Axiovert 200 M Marianas Digital
Microscopy Workstation (Intelligent Imaging Innovations, Den-
ver, CO).
Statistical Analysis
Statistical significance for group comparison was performed by
a Student’s t-Test or one way ANOVA followed by a Newman-
Keuls post-hoc analysis. The difference between groups was
considered significant when the P value was ,0.05.
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